The role of biomarker testing in NSCLC
touchMDT for touchONCOLOGY
Listen to a medical oncologist and a pathologist discuss the evolving role of biomarker testing in NSCLC in the light of emerging testing methodologies and treatment targets.
The multidisciplinary team
Medical oncologist: Dr Alexander Drilon, USA
Pathologist: Prof. Keith Kerr, UK
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.